Pharmacokinetics of SSRI antidepressants: Half-life and clinical applicability;Pharmacocinetique des ISRS: Notion de demi-vie d'elimination et implications cliniques

Encephale

Volumn 25, Issue 5, 1999, Pages 470-476

  Gury, Charles ^a   Cousin, F ^a  

^a NONE

Author keywords

Clinical use; Half life; Pharmacokinetic; SSRIs antidepressants

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; NORFLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN;

ARTICLE; DEPRESSION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; HUMAN; HALF LIFE TIME; LIVER; METABOLISM; REVIEW;

HALF-LIFE; HUMANS; LIVER; SEROTONIN UPTAKE INHIBITORS;

EID: 0032731650     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ADVERSE DRUG REACTIONS ADVISORY. Selective serotonin reuptake inhibitors and SIADH. Med J Austr 1996 ; 164 : 562.
2. ALLAIN H, MENARD G. La fluoxétine, relations entre le profil pharmacocinétique et les données cliniques. La Lett Pharmacol 1992 ; 6 (9) : 1-3.
3. ALTAMURA AC, MORO AR, PERCUDANI M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994 ; 26 (3) : 201-14.
4. ARONOFF GR, BERGSTROM RF, POTTRATZ ST et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984 ; 36 : 138-44.
5. BAUMANN P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996 ; 31 (6) : 444-6.
6. BAYER AJ, ROBERTS RA, ALLEN EA et al. The pharmacokinetics of paroxetine in the elderly. Acta Psych Scand 1989 ; 80 (Suppl 350) : 85-6.
7. BEASLEY CM, BOSOMWORTH JC, WERNICKE JF. Fluoxetine : relationships among dose, response adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990 ; 26 (1) : 18-24.
8. BENFIELD P, HEEL RC, LEWIS SP. Fluoxetine : a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986 ; 32 : 481-508.
9. BERGSTROM RF, LEMBERGER L, FARID N et al. Clinical pharmacology and pharmacokinetics of fluoxetine : a review. Br J Psychiatry 1988 ; 153 (Suppl 3) : 47-50.
10. BERGSTROM RF, WOLEN RL, LEMBERGER L. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988 ; 44 (3) : 353-9.
11. BLOMGREN SL. SSRI Dose interruption study : interim data. APA, poster 188 ; May 1997, San Diego (USA).
12. BORYS J, SETZER SC, LING LJ et al. Acute fluoxetine overdose : A report of 234 cases. Am J Emerg Med 1992 ; 10 (2) : 115-20.
13. COUPLAND NJ, BELL CJ, POTOKAR JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996 ; 16 (5) : 356-62.
14. CREWE HK, LENNARD MS, TUCKER GT et al. The effect of SSRI on cytochrome P450-2D6 activity in human liver microsomes. Br J Clin Pharmacol 1992 ; 34 : 262-5.
15. DE VANE CL. Pharmacokinetics and drug metabolism of newer antidepressants agents. J Clin Psychiatry 1994 ; 55 (Suppl 12) : 38-42.
16. DOYLE GD, LAHER M, KELLY JG et al. The pharmacokinetics of paroxetine in renal impairment. Acta Psych Scand 1989 ; 80 (Suppl 350) : 89-90.
17. FREDERICSON K. Kinetics of citalopram in elderly patients. Psychopharmacol 1985 ; 86 : 253-7.
18. GOODNICK PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994 ; 27 (4) : 307-30.
19. GRAM LF. Fluoxetine. N Engl J Med 1994 ; 331 : 1354-61.
20. GREENBLATT DJ. Basic pharmacokinetic principles and their application to psychotropic drugs. J Clin Psychiatry 1993 ; 54 (Suppl 9) : 8-13.
21. GUPTA RK, PARKER G, NORMAN TR. Fluoxetine-delayed half-time and an adverse event. Med J Austr 1993 ; 158 (10) : 722-3.
22. KAM PC, CHANG GW. Selective serotonin reuptake inhibitors, pharmacology and clinical implications in anesthesia and critical care medicine. Anaesthesia 1997 ; 52 : 982-8.
23. LABAUNE JP. Pharmacocinétique, principes fondamentaux. Paris : Masson, 1984.
24. LEJOYEUX M. Le syndrome d'interruption brutale des antidépresseurs : des spécificités parmi les ISRS. Abstract Neuro & Psy 1997 ; 169 : 1-5
25. LEONARD BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993 ; 54 (Suppl 8) : 3-15.
26. LEONARD BE. SSRI differentiation : pharmacology and pharmacokinetics. Hum Psychopharmacol 1995 ; 10 : 5149-58.
27. MAGRON P, HIDA H, DE BEAUCHAMP I. Le syndrome sérotoninergique. J Pharm Clin 1997 ; 16 : 13-8.
28. MITCHELL PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997 ; 17 (6) : 390-406.
29. PRESKORN SH. Pharmacokinetics of antidepressants : why and how they are relevant to treatment. J Clin Psychiatry 1993 ; 54 (Suppl 9) : 14-34.
30. PRICE JS, WALLER PC, WOOD SM et al. A comparison of the post-marketing safety of four SSRI including the investigation of symptoms occuring on withdrawal. Br J Clin Pharmacol 1996 ; 42 : 757-63.
31. ROSENBAUM JF, FAVA M, HOOG SL et al. Selective serotonin reuptake inhibitor discontinuation syndrome : a randomized clinical trial. Biol Psychiatry 1998 ; 44 : 77-87.
32. STERNBACH H. The serotonin syndrom. Am J Psychiatry 1991 ; 148 : 705-13.
33. ZAJECKA J, FAWCETT J, AMSTERDAM J et al. Safety of abrupt discontinuation of fluoxetine : a randomized, placebo-controlled study. J Clin Psychopharmacol 1998 ; 18 : 193-7.